Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 17, 2013
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4,...
-
Dec 16, 2013
The Board of Directors of Boston Scientific Corporation (NYSE: BSX) has elected David Roux as a Director. The appointment of Mr. Roux will fill a...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority,...
-
Dec 6, 2013New Retrospective Data Presented at NANS 2013 Show Highly Significant Reduction in Pain and High Trial Therapy Success Rate of Precision Spectra in the Treatment of Chronic Pain
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate...
-
Dec 6, 2013
Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the...
-
Nov 25, 2013Advanced Stent Technology to Launch Immediately in the United States
Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...
-
Nov 22, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 25th Annual Piper Jaffray Healthcare Conference on December 3 in New...
-
Nov 21, 2013
Boston Scientific Corporation (NYSE: BSX) announces the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective...
-
Nov 19, 2013Boston Scientific Receives FDA Clearance And CE Mark Approval For Direxion™ Torqueable MicrocatheterProprietary Shaft Design Enables Better Control In Hard-To-Navigate Vessels
Further bolstering its market-leading portfolio of peripheral embolization technologies, Boston Scientific Corporation (NYSE: BSX) has received U.S....
-
Nov 19, 2013First System To Selectively Stimulate Targeted Areas Of The Brain To Manage Symptoms of Debilitating Disease
The Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment...